0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV50.79%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cytek Biosciences Stock Discussion
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
On May 28, 2024, Cytek Biosciences (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails received approval from China's National Medical Products Administration (NMPA) for clinical use. These reagents, used in the Cytek Northern Lights-Clinical (NL-CLC) cell analysis systems, aid in diagnosing and monitoring immune-related conditions...
NEWS
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
Cytek Biosciences has introduced the Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ and Cytek Northern Lights™ systems. This upgrade allows researchers to detect subcellular particles, such as extracellular vesicles (EVs), with superior sensitivity and resolution. The global EV market is projected to grow significantly, from $227.5...
In reaction to earnings/guidance:
• $PDD Holdings (PDD.US)$ +15% (The company said its performance was boosted by a recovery in consumer sentiment.)
Other news:
• $Hill International (HIL.US)$ +20% (Hill International and GISI announce enhancements to their strategic merger agreement)
• $FiscalNote Holdings (NOTE.US)$ +11.3% (files for 87,504,863 share common stock offering, relates to warrants)
• $Cytek Biosciences (CTKB.US)$ +2.9% (fi...
No comment yet